Illumina pioneered Next Generation Sequencing (NGS) of DNA, a highly accurate and relatively affordable DNA sequencing technology. As market leader, Illumina quadruple its revenues in 10 years, ...

SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now ...

At its ongoing genomics forum, narrow-moat Illumina finally gave investors a glimpse of its new product pipeline, which could help it stave off new entrants in its legacy sequencing business. While ...

At this year’s American Society of Human Genetics (ASHG) annual meeting, Illumina showcased its latest innovations designed to push the boundaries of genomic discovery and clinical research. Among ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples "Illumina Complete Long Reads is more convenient than ...